Zoetis Inc. $ZTS Shares Sold by Trivium Point Advisory LLC

Key Points

• Trivium Point Advisory LLC has reduced its holdings in Zoetis Inc. by 10.6%, selling 1,938 shares during the first quarter, leaving it with 16,315 shares valued at $2.68 million.
• Zoetis reported a quarterly earnings per share of $1.76, exceeding expectations, with revenue increasing by 4.2% year-over-year to $2.46 billion.
• The company has declared a quarterly dividend of $0.50, with a current yield of 1.3%, demonstrating a dividend payout ratio of 34.42%.

Trivium Point Advisory LLC cut its holdings in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 10.6% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 16,315 shares of the company's stock after selling 1,938 shares during the period. Trivium Point Advisory LLC's holdings in Zoetis were worth $2,686,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of the business. Kovitz Investment Group Partners LLC grew its position in shares of Zoetis by 23.7% during the first quarter. Kovitz Investment Group Partners LLC now owns 196,490 shares of the company's stock worth $32,352,000 after acquiring an additional 37,700 shares during the last quarter. Vestmark Advisory Solutions Inc. grew its position in shares of Zoetis by 95.1% during the first quarter. Vestmark Advisory Solutions Inc. now owns 19,086 shares of the company's stock worth $3,143,000 after acquiring an additional 9,302 shares during the last quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund grew its position in shares of Zoetis by 9.8% during the first quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 111,811 shares of the company's stock worth $18,410,000 after acquiring an additional 10,000 shares during the last quarter. Holderness Investments Co. grew its position in shares of Zoetis by 6.4% during the first quarter. Holderness Investments Co. now owns 4,962 shares of the company's stock worth $817,000 after acquiring an additional 299 shares during the last quarter. Finally, Financial Network Wealth Advisors LLC grew its position in shares of Zoetis by 38.3% during the first quarter. Financial Network Wealth Advisors LLC now owns 914 shares of the company's stock worth $150,000 after acquiring an additional 253 shares during the last quarter. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities analysts recently weighed in on ZTS shares. Stifel Nicolaus lowered shares of Zoetis from a "buy" rating to a "hold" rating and lowered their price objective for the company from $165.00 to $160.00 in a research report on Wednesday, June 18th. Leerink Partners lowered shares of Zoetis from an "outperform" rating to a "market perform" rating and lowered their price objective for the company from $180.00 to $155.00 in a research report on Thursday, July 17th. Piper Sandler lifted their price objective on shares of Zoetis from $210.00 to $215.00 and gave the company an "overweight" rating in a research report on Monday, August 11th. Leerink Partnrs lowered shares of Zoetis from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 17th. Finally, UBS Group lowered their price objective on shares of Zoetis from $189.00 to $170.00 and set a "neutral" rating on the stock in a research report on Wednesday, May 7th. Four analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat.com, Zoetis has an average rating of "Moderate Buy" and a consensus target price of $202.43.

Insider Transactions at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 652 shares of Zoetis stock in a transaction dated Tuesday, June 3rd. The shares were sold at an average price of $170.00, for a total transaction of $110,840.00. Following the completion of the transaction, the executive vice president owned 15,129 shares in the company, valued at approximately $2,571,930. The trade was a 4.13% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 0.16% of the company's stock.

Zoetis Price Performance

Zoetis stock traded up $2.23 during midday trading on Tuesday, reaching $154.55. The company's stock had a trading volume of 932,776 shares, compared to its average volume of 3,099,500. Zoetis Inc. has a fifty-two week low of $139.70 and a fifty-two week high of $200.33. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.04 and a current ratio of 1.76. The stock's 50 day simple moving average is $154.69 and its 200 day simple moving average is $158.90. The firm has a market capitalization of $68.49 billion, a PE ratio of 26.61, a P/E/G ratio of 2.47 and a beta of 0.88.

Zoetis (NYSE:ZTS - Get Free Report) last released its earnings results on Tuesday, August 5th. The company reported $1.76 EPS for the quarter, beating analysts' consensus estimates of $1.62 by $0.14. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The company had revenue of $2.46 billion during the quarter, compared to the consensus estimate of $2.41 billion. During the same quarter last year, the company earned $1.56 earnings per share. Zoetis's quarterly revenue was up 4.2% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, equities research analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 3rd. Shareholders of record on Friday, July 18th will be issued a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a yield of 1.3%. The ex-dividend date is Friday, July 18th. Zoetis's dividend payout ratio (DPR) is 34.42%.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.